Pictured: An infant using the EarGenie protoype.
Project title: EarGenie: personalised management of hearing impairment for infants
BMTH Round: One
EarGenie is an innovative system for personalised management of hearing impairment aiming to enable life-long benefits, using a novel combination of electrophysiology and functional near-infrared spectroscopy (fNIRS) to perform a diagnostic hearing evaluation.
Deaf infants face delayed and inadequate language development, affecting education, social participation, and even employment later in life. Major contributing factors are the delay between diagnosis and the selection and accurate adjustment of hearing devices, delayed individualised optimisation of device features, and difficulty choosing a specific therapy to optimise language development. EarGenie is set to transform the precision of diagnosis and optimisation of hearing instrument function, to deliver major benefit to language development in deaf children. This project will allow for the development of a clinical prototype as well as plans for regulatory approval and clinical trials.
Visit Bionics Institute for more information.
LinkedIn: Bionics Institute
|Consortium Lead||Bionics Institute|
|Consortium Partners||Hydrix, Taralye Early Intervention Centre, Plunkett Consulting Group, Australian Hearing|
MTPConnect grant: $966,500
Industry contribution: $2,935,387
|Duration||May 2018 - July 2021 (Terminated)|
|Outcomes||Bionics Institute has finished the Speech Module of the EarGenie. This system objectively assesses whether an infant can hear speech and also whether an infant can discriminate between two different speech sounds.|
|Contact||Professor Colette McKay, Leader of Translational Hearing Research|